Abstract 404P
Background
Patients with advanced lung cancer are considered to have a poor prognosis, and recent studies have shown that immunotherapy appears to be associated with improved prognosis and prolonged survival significantly compared with chemotherapy. However, immunotherapy may refer to a comparatively high medical cost and bring severe financial toxicity to patients. In the treatment course of patients with advanced lung cancer, much attention was paid to the safety and efficacy of medications, rather than financial toxicity, which may affect the prognosis and survival indeed. In that case, it is necessary to weigh the profit and the financial toxicity led by immunotherapy.
Methods
We performed a systematic search in Medline on the cost-effectiveness of immunotherapy in patients with advanced lung cancer, and 16 studies were included, consisting of 6 countries, We systematically reviewed the incremental cost for improved quality-adjusted life years (QALYs) and incremental cost-effectiveness ratio (ICER) in patients treated with immunotherapy with respect to different countries and different tumor proportion score (TPS) of programmed death receptor-1 ligand (PD-L1).
Results
We found that the willingness to pay (WTP) was not significantly associated with ICER among three western countries (P=0.354). Patients with TPS ≥50%, ≥20%, or ≥1% showed no significant differences in elevated QALYs (P=0.148) and ICER (P=0.263). The elevated QALYs (P=0.024) and ICER of Pembrolizumab were significantly higher than that of Atezolizumab (P=0.045), while there was no significant difference in the cost of elevated QALY between Pembrolizumab and Atezolizumab (P=0.747).
Conclusions
Patients with advanced lung cancer would get profit in the treatment of immunotherapy from different countries, while Pembrolizumab would be associated with a higher benefit and less financial toxicity when taking cost-effectiveness analysis into account. Thus, patients would get more in the immunotherapy when financial toxicity was taken into consideration, and it is necessary to integrate financial toxicity in the clinical decision.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
133P - Which patient subgroup needs more attention in early treatment failure? A matched cohort study of treatment failure patterns in locally advanced gastric cancer
Presenter: Dong Wu
Session: e-Poster Display Session
134P - Effect of preoperative tumour under-staging on the long-term survival of patients undergoing radical gastrectomy for gastric cancer
Presenter: Mi Lin
Session: e-Poster Display Session
135P - Significance of lymphatic invasion in the indication for additional gastrectomy after endoscopic treatment
Presenter: Hirohito Fujikawa
Session: e-Poster Display Session
136P - Modified ypTNM staging classification for gastric cancer after neoadjuvant therapy: A multi-institutional study
Presenter: Wen-Wu Qiu
Session: e-Poster Display Session
137P - Clinical utility of circulating tumour DNA (ctDNA) in resectable gastric cancer (GC)
Presenter: Mikhail Fedyanin
Session: e-Poster Display Session
138P - Prognostic importance of dynamic changes in systemic inflammatory markers for patients with gastric cancer
Presenter: Ying-Qi Huang
Session: e-Poster Display Session
139P - An intraoperative model for predicting survival and deciding therapeutic schedules: A comprehensive analysis of peritoneal metastasis in patients with advanced gastric cancer
Presenter: Zhi-Yu Liu
Session: e-Poster Display Session
140P - Preoperative and postoperative C-reactive protein levels predict recurrence and chemotherapy benefit in gastric cancer
Presenter: Li-Li Shen
Session: e-Poster Display Session
141P - Low expression of CDK5RAP3 and UFM1 indicates poor prognosis in patients with gastric cancer
Presenter: Ning-Zi Lian
Session: e-Poster Display Session
142P - Prognostic analysis of patients with intra-abdominal infectious complications after laparoscopy and open radical gastrectomy for gastric cancer: A propensity score-matching analysis
Presenter: Si-Jin Que
Session: e-Poster Display Session